Latest stories on LXEO
Oppenheimer reiterates Lexeo Therapeutics stock rating on trial data
Investing.com Analyst Ratings52 · neutralanalyst
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
GlobeNewswire56 · neutralproduct/pr
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
Business Insider56 · neutralproduct/pr
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow
Seeking Alpha52 · neutralproduct/pr
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
Seeking Alpha52 · neutralproduct/pr
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
GlobeNewswire52 · neutralproduct/pr
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
Business Insider52 · neutralproduct/pr
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
GlobeNewswire52 · neutralproduct/pr
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $17
Investing.com Analyst Ratings61 · neutralanalyst
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Business Insider63 · neutralproduct/pr
Lexeo Therapeutics, Inc. (LXEO) files 8-K
SEC 8-K50 · neutralgeneral
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
PR Newswire56 · neutralproduct/pr
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
GlobeNewswire56 · neutralgeneral
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Business Insider56 · neutralgeneral
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
Seeking Alpha50 · neutralm&a
Lexeo Therapeutics, Inc. (LXEO) Mantle Therapeutics Inc. - M&A Call - Slideshow
Seeking Alpha65 · bullishm&a
Baird reiterates Lexeo Therapeutics stock rating on acquisition deal
Investing.com Analyst Ratings56 · neutralanalyst
Why is Lexeo Therapeutics stock gaining today?
Investing.com Markets55 · neutralgeneral
Lexeo stock rises on $21.3M Mantle deal for FA therapies
Investing.com Markets67 · bullishm&a
Lexeo Therapeutics enter into agreement to acquire Mantle Therapeutics
The Fly62 · neutralm&a
Lexeo Therapeutics, Inc. (LXEO) files 8-K
SEC 8-K50 · neutralgeneral
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
GlobeNewswire56 · neutralgeneral